A Phase 1, Randomized, Placebo controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ACP-014 in Healthy Adult Subjects (ACP-014 -Phase 1)
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2018
At a glance
- Drugs TransCon PTH (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; First in man
- Sponsors Ascendis Pharma Bone Diseases
- 30 May 2018 According to the Ascendis Pharma media release, data from the complete multiple ascending dose cohorts were presented at the European Congress of Endocrinology.
- 30 May 2018 Status changed from recruiting to completed, according to the Ascendis Pharma media release.
- 07 May 2018 According to an Ascendis Pharma media release, data will be presented at the European Congress of Endocrinology (ECE) 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History